Recent advances in the treatment of adult T‐cell leukemia‐lymphomas

Cancer Science

Atae Utsunomiya³  Ilseung Choi²  Dai Chihara¹ 

[1] Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan;Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan;Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan

关键词: Adult T‐cell leukemia‐lymphoma;    allogeneic hematopoietic stem cell transplantation;    antiviral therapy;    chemotherapy;    molecular targeted therapy;   

DOI  :  10.1111/cas.12617

来源: Wiley

【 摘 要 】

Abstract

Recent advances in treatment for adult T-cell leukemia-lymphoma (ATL) are reviewed herein. It is currently possible to select a therapeutic strategy for ATL and predict prognosis by classification of patients by clinical subtypes and clinicopathological factors. Although the overall survival (OS) of patients with ATL has increased marginally because of advances in chemotherapy, further prolongation of survival might be difficult with conventional chemotherapy alone. Promising results have been reported for antiviral therapy using zidovudine and interferon-α, and, indeed, antiviral therapy is currently the standard treatment for patients with ATL in western countries. Remarkably, the 5-year OS rates are 100% for both the smoldering-type and chronic-type ATL. Recently, treatments for ATL have included allogeneic hematopoietic stem cell transplantation and molecular targeted therapies. Furthermore, the anti-CCR4 monoclonal antibody mogamulizumab has been shown to have marked cytotoxic effects on ATL cells, especially in the leukemic type of ATL. In the lymphoma type of ATL, the response rate may be improved by combining mogamulizumab with chemotherapy. It should be recognized that prevention of infection from carriers of human T-cell leukemia virus type-I and transfer of the virus from mother to infant are crucial issues for the eradication of ATL.

【 授权许可】

CC BY-NC   
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.